ARC and Sangivamycin: Similarities in Cancer Cell Activity
Author Information
Author(s): Stockwin Luke H, Yu Sherry X, Stotler Howard, Hollingshead Melinda G, Newton Dianne L
Primary Institution: Developmental Therapeutics Program, SAIC-Frederick Inc., NCI- Frederick, Frederick, MD, USA
Hypothesis
Does ARC (NSC 188491) exhibit similar anti-cancer activity to Sangivamycin (NSC 65346)?
Conclusion
ARC shows similar in vitro biological activity to Sangivamycin but requires further studies before clinical development.
Supporting Evidence
- ARC and Sangivamycin both inhibit protein kinase C and P-TEFb.
- ARC shows similar cytotoxicity profiles to Sangivamycin in various cancer cell lines.
- Both drugs induce apoptosis and block the cell cycle in a similar manner.
Takeaway
ARC is a new cancer drug that works like an older drug called Sangivamycin, but we need to do more tests before using it in people.
Methodology
The study used structure-based homology searches, viability assays, cell cycle and apoptosis assays, gene-expression analysis, and kinase inhibition assays.
Limitations
ARC was found to be inactive in several xenograft models, likely due to rapid serum clearance.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website